Generic Name and Formulations:
Ethotoin 250mg; tabs.
Recordati Rare Diseases, Inc.
Indications for PEGANONE:
For the control of tonic-clonic (grand mal) and complex partial (psychomotor) seizures.
Take after food. Individualize. Give in 4 to 6 divided doses daily. Initially 1g or less daily, with subsequent gradual dose increases over a period of several days. Usual maintenance: 2–3g daily.
<1yr: not recommended. ≥1yr: Take after food. Individualize. Give in 4 to 6 divided doses daily. Initial max 750mg daily. Usual maintenance: 500mg–1g daily, although occasionally 2g or (rarely) 3g daily may be necessary. Concomitant other antiepileptic: reduce dose while increasing Peganone dose.
Hepatic abnormalities. Hematologic disorders.
Monitor for emergence of depression, suicidal thoughts/behavior, and/or unusual changes in mood/behavior. Hepatic dysfunction: perform LFTs; discontinue if liver damage occurs. Monitor blood counts, urinalysis when therapy is begun and at monthly intervals for several months thereafter. Pregnancy (Cat. D; avoid). Nursing mothers: not recommended.
Caution with coumarin anticoagulants; monitor.
GI upset, chest pain, nystagmus, diplopia, fever, dizziness, headache, insomnia, fatigue, numbness, rash, Stevens-Johnson syndrome, blood dyscrasias, ataxia, gum hypertrophy, lymphadenopathy (withdraw if occurs), systemic lupus erythematosus.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies